The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol.
cannabidiol
cognition
driving simulation
medicinal cannabis
mobile drug testing
psychomotor
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
03
02
2020
revised:
16
05
2020
accepted:
28
05
2020
pubmed:
31
7
2020
medline:
15
9
2021
entrez:
31
7
2020
Statut:
ppublish
Résumé
Interest in the use of cannabidiol (CBD) is increasing worldwide as its therapeutic effects are established and legal restrictions moderated. Unlike Δ Thirty healthy individuals will be recruited to participate in this randomised, double-blind, placebo-controlled crossover trial. Participants will complete four research sessions each involving two 30-min simulated driving performance tests completed 45 and 210 min following oral ingestion of placebo or 15, 300, or 1,500 mg CBD. Cognitive function and subjective drug effects will be measured, and blood and oral fluid sampled, at regular intervals. Oral fluid drug testing will be performed using the Securetec DrugWipe® 5S and Dräger DrugTest® 5000 devices to determine whether CBD increases the risk of "false-positive" roadside tests to Δ This study will clarify the risks involved in driving following CBD use and assist in ensuring the safe use of CBD by drivers.
Substances chimiques
Cannabidiol
19GBJ60SN5
Types de publication
Clinical Trial Protocol
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2749Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM)-V. Retrieved from www.psychiatry.org/psychiatrists/practice/dsm
Anderson, B. M., Rizzo, M., Block, R. I., Pearlson, G. D., & O'Leary, D. S. (2010). Sex differences in the effects of marijuana on simulated driving performance. Journal of Psychoactive Drugs, 42(1), 19-30.
Anderson, L. L., Absalom, N. L., Abelev, S. V., Low, I. K., Doohan, P. T., Martin, L. J., … Arnold, J. C. (2019). Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 60(11), 2224-2234.
Arkell, T. R., Kevin, R. C., Stuart, J., Lintzeris, N., Haber, P. S., Ramaekers, J. G., & McGregor, I. S. (2019). Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. Drug Testing and Analysis, 11, 1486-1497.
Arkell, T. R., Lintzeris, N., Kevin, R. C., Ramaekers, J. G., Vandrey, R., Irwin, C., … McGregor, I. S. (2019). Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 236(9), 2713-2724.
Armstrong, L., Pumerantz, A., Fiala, K., Roti, M., Kavouras, S., Casa, D., & Maresh, C. (2010). Human hydration indices: Acute and longitudinal reference values. International Journal of Sport Nutrition and Exercise Metabolism, 20(2), 145-153.
Arndt, D., & de Wit, H. (2017). Cannabidiol does not dampen responses to emotional stimuli in healthy adults. Cannabis and Cannabinoid Research, 2(1), 105-113.
Bergamaschi, M., Queiroz, H., Zuardi, R., Crippa, A., & Alexandre, S. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Reserach in Drug Safety, 6(4), 237-249.
Bergamaschi, M., Queiroz, R., Chagas, M., de Oliveira, D., De Martinis, B., Kapczinski, F., … Crippa, J. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219-1226.
Berthelon, C., & Gineyt, G. (2014). Effects of alcohol on automated and controlled driving performances. Psychopharmacology, 231(10), 2087-2095.
Bhattacharyya, S., Fusar-Poli, P., Borgwardt, S., Martin-Santos, R., Nosarti, C., O'Carroll, C., … Crippa, J. (2009). Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: A neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry, 66(4), 442-451.
Birnbaum, A., Karanam, A., Marino, S., Barkley, C., Remmel, R., Roslawski, M., … Leppik, I. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia, 60, 1586-1592.
Boggs, D., Nguyen, J., Morgenson, D., Taffe, M., & Ranganathan, M. (2018). Clinical and preclinical evidence for functional interactions of cannabidiol and delta(9)-tetrahydrocannabinol. Neuropsychopharmacology, 43(1), 142-154.
Boggs, D., Surti, T., Gupta, A., Gupta, S., Niciu, M., Pittman, B. M. S., … Ranganathan, M. (2018). The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology, 235(7), 1923-1932.
Bonn-Miller, M., Loflin, M., Thomas, B., Marcu, J., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. Journal of the American Medical Association, 318(17), 1708-1709.
Borenstein, M., Hedges, L., Higgins, J., & Rothstein, H. (2009). Introduction to meta-analysis. West Sussex: John Wiley & Sons Ltd.
Borgwardt, S., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J., Seal, M., … O'Carroll, C. (2008). Neural basis of Δ-9-tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biological Psychiatry, 64(11), 966-973.
Bosker, W. M., Kuypers, K. P. C., Theunissen, E. L., Surinx, A., Blankespoor, R. J., Skopp, G., … Ramaekers, J. G. (2012). Medicinal delta(9)-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests. Addiction, 107(10), 1837-1844.
Centre for Road Safety NSW. (2016). Road traffic casualty crashes in New South Wales - Statistical statement for the year ended December 31, 2015 Retrieved from https://roadsafety.transport.nsw.gov.au/downloads/crashstats2015.pdf
Chen, J. W., Borgelt, L. M., & Blackmer, A. B. (2019). Cannabidiol: A new hope for patients with dravet or Lennox-Gastaut syndromes. Annals of Pharmacotherapy, 53(6), 603-611.
Cousineau, D., Brown, S., & Heathcote, A. (2004). Fitting distributions using maximum likelihood: Methods and packages. Behavior Research Methods Instruments & Computers, 36(4), 742-756.
Crippa, J., Derenusson, G., Ferrari, T., Wichert-Ana, L., Duran, F., Martin-Santos, R., … Hallak, J. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology, 25(1), 121-130.
Dalton, W., Martz, R., Lemberger, L., Rodda, B., & Forney, R. (1976). Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clinical Pharmacology & Therapeutics, 19(3), 300-309.
Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011). Effects of benzodiazepines, antidepressants and opioids on driving. Drug Safety, 34(2), 125-156.
Devinsky, O., Cross, H., Laux, L., Marsh, E., Miller, I., Nabbout, R., … Wright, S. (2017). Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. New England Journal of Medicine, 376(21), 2011-2020.
Devinsky, O., Patel, A., Cross, H., Villanueva, V., Wirrell, E., Privitera, M., … Zuberi, S. (2018). Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New England Journal of Medicine, 378(20), 1888-1897.
Downey, L. A., King, R., Papafotiou, K., Swann, P., Ogden, E., Boorman, M., & Stough, C. (2013). The effects of cannabis and alcohol on simulated driving: Influences of dose and experience. Accident Analysis and Prevention, 50, 879-886.
Furtwaengler, N. A., & de Visser, R. O. (2013). Lack of international consensus in low-risk drinking guidelines. Drug and Alcohol Review, 32(1), 11-18.
Fusar-Poli, P., Crippa, J., Bhattacharyya, S., Borgwardt, S., Allen, P., Martin-Santos, R., … Atakan, Z. (2009). Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry, 66(1), 95-105.
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015). Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia, 56(8), 1246-1251.
George, S., Clark, M., & Crotty, M. (2007). Development of the Adelaide driving self-efficacy scale. Clinical Rehabilitation, 21(1), 56-61.
Griffin, S. E., Robergs, R. A., & Heyward, V. H. (1997). Blood pressure measurement during exercise: A review. Medicine and Science in Sports and Exercise, 29(1), 149-159.
Hartley, S., Simon, N., Larabi, A., Vaugier, I., Barbot, F., Quera-Salva, M. A., & Alvarez, J. C. (2019). Effect of smoked cannabis on vigilance and accident risk using simulated driving in occasional and chronic users and the pharmacokinetic-pharmacodynamic relationship. Clinical Chemistry, 65(5), 684-693.
Hartman, R. L., Brown, T. L., Milavetz, G., Spurgin, A., Pierce, R. S., Gorelick, D. A., … Huestis, M. A. (2015). Cannabis effects on driving lateral control with and without alcohol. Drug and Alcohol Dependence, 154, 25-37.
Hartman, R. L., Brown, T. L., Milavetz, G., Spurgin, A., Pierce, R. S., Gorelick, D. A., … Huestis, M. A. (2016). Cannabis effects on driving longitudinal control with and without alcohol. Journal of Applied Toxicology, 36(11), 1418-1429.
Herrmann, E., Cone, E., Mitchell, J., Bigelow, G., LoDico, C., Flegel, R., & Vandrey, R. (2015). Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. Drug and Alcohol Dependence, 151, 194-202.
Hindocha, C., Freeman, T., Schafer, G., Gardener, C., Das, R., Morgan, C., & Curran, V. (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. European Neuropsychopharmacology, 25(3), 325-334.
Hundal, H., Lister, R., Evans, N., Antley, A., Englund, A., Murray, R., … Morrison, P. (2017). The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. Journal of Psychopharmacology, 32(3), 276-282.
Ibeas, B., Chen, T., Nunn, A., Bazelot, M., Dallas, M., & Whalley, B. (2015). Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics, 12(4), 699-730.
Irwin, C., Iudakhina, E., Desbrow, B., & McCartney, D. (2017). Effects of acute alcohol consumption on measures of simulated driving: A systematic review and meta-analysis. Accident Analysis & Prevention, 102, 248-266.
Irwin, C., Shum, D., Leveritt, M., & Desbrow, B. (2013). Test-retest reliability of simulated driving performance: A pilot study. Paper presented at the Proceedings of the Seventh International Driving Symposium on Human Factors in Driver Assessments, Training and Vehicle Design, Bolton Landing, New York.
Jamison, R. N., Schein, J. R., Vallow, S., Ascher, S., Vorsanger, G. J., & Katz, N. P. (2003). Neuropsychological effects of long-term opioid use in chronic pain patients. Journal of Pain and Symptom Management, 26(4), 913-921.
Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974). Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man. European Journal of Pharmacology, 28(1), 172-177.
Kennedy, R., Lane, N., Berbaum, K., & Lilienthal, M. (1993). Simulator sickness questionnaire: An enhanced method for quantifying simulator sickness. The International Journal of Aviation Psychology, 3(3), 203-220.
Kenntner-Mabiala, R., Kaussner, Y., Jagiellowicz-Kaufmann, M., Hoffmann, S., & Krüger, H.-P. (2015). Driving performance under alcohol in simulated representative driving tasks: An alcohol calibration study for impairments related to medicinal drugs. Journal of Clinical Psychopharmacology, 35(2), 134-142.
Kleykamp, B., Griffiths, R., & Mintzer, M. (2010). Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers. Experimental and Clinical Psychopharmacology, 18(1), 1-16.
Kroenke, K., Spitzer, R., & Williams, J. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606-613.
Lakens, D. (2013). Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Frontiers in Psychology, 4, 863.
Lanz, J., Kim, W.-K., Walther, T., Burgdorf, C., Möllmann, H., Linke, A., … Pilgrim, T. (2019). Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: A randomised non-inferiority trial. The Lancet, 394(10209), 1619-1628.
Lattanzi, S., Brigo, F., Trinka, E., Zaccara, G., Cagnetti, C., Del Giovane, C., & Silvestrini, M. (2018). Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis. Drugs, 78(17), 1791-1804.
Leas, E. C., Nobles, A. L., Caputi, T. L., Dredze, M., Smith, D. M., & Ayers, J. W. (2019). Trends in internet searches for cannabidiol (CBD) in the United States. JAMA Network Open, 2(10), e1913853-e1913853.
Lee, D., Milman, G., Schwope, D. M., Barnes, A. J., Gorelick, D. A., & Huestis, M. A. (2012). Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. Clinical Chemistry, 58(7), 1101-1109.
Lenne, M. G., Dietze, P. M., Triggs, T. J., Walmsley, S., Murphy, B., & Redman, J. R. (2010). The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. Accident Analysis and Prevention, 42(3), 859-866.
Leweke, F., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C., Hoyer, C., … Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2(3), e94-e94.
Leweke, M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. (2000). Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacology Biochemistry and Behavior, 66(1), 175-181.
Linares, I., Zuardi, A., Pereira, L., Queiroz, R., Mechoulam, R., Guimaraes, F., & Crippa, J. (2019). Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Brazilian Journal of Psychiatry, 41(1), 9-14.
Lorenz, J., Beck, H., & Bromm, B. (1997). Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain. Pain, 73(3), 369-375.
Marteau, T., & Bekker, H. (1992). The development of a six-item short-form of the state scale of the Spielberger state-trait anxiety inventory (STAI). British Journal of Clinical Psychology, 31, 301-306.
McCartney, D., Desbrow, B., & Irwin, C. (2017). The effect of fluid intake following dehydration on subsequent athletic and cognitive performance: A systematic review and meta-analysis. Sports Medicine, 3(1), 13.
McGuire, P., Robson, P., Cubala, W., Vasile, D., Morrison, P., Barron, R., … Wright, S. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225-231.
McLeod, D., Griffiths, R., Bigelow, G., & Yingling, J. (1982). An automated version of the digit symbol substitution test (DSST). Behavior Research Methods and Instrumentation, 14(5), 463-466.
Merrick, J., Lane, B., Sebree, T., Yaksh, T., O'Neill, C., & Banks, S. (2016). Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid. Cannabis and Cannabinoid Research, 1(1), 102-112.
Mets, M. A., Kuipers, E., de Senerpont Domis, L. M., Leenders, M., Olivier, B., & Verster, J. C. (2011). Effects of alcohol on highway driving in the STISIM driving simulator. Human Psychopharmacology: Clinical and Experimental, 26(6), 434-439.
Micallef, J., Dupouey, J., Jouve, E., Truillet, R., Lacarelle, B., Taillard, J., … Mestre, D. (2018). Cannabis smoking impairs driving performance on the simulator and real driving: A randomized, double-blind, placebo-controlled, crossover trial. Fundamental & Clinical Pharmacology, 32(5), 558-570.
Monti, J. (1977). Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology, 55(3), 263-265.
Morrison, G., Crockett, J., Blakey, G., & Sommerville, K. (2019). A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clinical Pharmacology in Drug Development, 8(8), 1009-1031.
Murillo-Rodríguez, E., Millán-Aldaco, D., Palomero-Rivero, M., Mechoulam, R., & Drucker-Colín, R. (2006). Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Letters, 580(18), 4337-4345.
National Academies of Sciences Engineering and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research, NW Washington, DC: National Academies Press.
Owens, K., & Ramaekers, J. G. (2009). Drugs, driving, and models to measure driving impairment. In J. Verster, S. Pandi-Perumal, J. Ramaekers, & d. G. J. (Eds.), Drugs, driving and Trraffic safety (pp. 43-58). Birkhauser Verlag AG: Basel, Switzerland.
Papafotiou, K., Carter, J. D., & Stough, C. (2005). The relationship between performance on the standardised field sobriety tests, driving performance and the level of delta 9-tetrahydrocannabinol (THC) in blood. Forensic Science International, 155(2-3), 172-178.
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., … Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175, 133-150.
Quertemont, E. (2011). How to statistically show the absence of an effect. Psychologica Belgica, 51(2), 109-127.
Richman, J. (2019). An investigation of the Druid® smartphone/tablet app as a rapid screening assessment for cognitive and psychomotor impairment associated with alcohol intoxication. Vision Development & Rehabilitation, 5(1), 31-42.
Rogeberg, O., & Elvik, R. (2016). The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction, 111(8), 1348-1359.
Rogeberg, O., & Elvik, R. (2017). Response to Li et al. (2017): Cannabis use and crash risk in drivers. Addiction, 112(7), 1316-1316.
Sateia, M. J. (2014). International classification of sleep disorders. Chest, 146(5), 1387-1394.
Spielberger, C. (1983). Manual for the state-trait anxiety inventory STAI (form Y). Palo Alto, CA.
Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018). A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs, 32(11), 1053-1067.
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., … Sommerville, K. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 391(10125), 1085-1096.
Vandrey, R., Herrmann, E. S., Mitchell, J. M., Bigelow, G. E., Flegel, R., LoDico, C., & Cone, E. J. (2017). Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. Journal of Analytical Toxicology, 41(2), 83-99.
Veldstra, J. L., Bosker, W. M., de Waard, D., Ramaekers, J. G., & Brookhuis, K. A. (2015). Comparing treatment effects of oral THC on simulated and on-the-road driving performance: Testing the validity of driving simulator drug research. Psychopharmacology, 232(16), 2911-2919.
Veldstra, J. L., Brookhuis, K. A., de Waard, D., Molmans, B. H., Verstraete, A. G., Skopp, G., & Jantos, R. (2012). Effects of alcohol (BAC 0.5 per thousand) and ecstasy (MDMA 100 mg) on simulated driving performance and traffic safety. Psychopharmacology, 222(3), 377-390.
Watanabe, K., Itokawa, Y., Yamaori, S., Funahashi, T., Kimura, T., Kaji, T., … Yamamoto, I. (2007). Conversion of cannabidiol to Δ9-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice. Forensic Toxicology, 25(1), 16-21.
Watson, P., Whale, A., Mears, S. A., Reyner, L. A., & Maughan, R. J. (2015). Mild hypohydration increases the frequency of driver errors during a prolonged, monotonous driving task. Physiology & Behavior, 147, 313-318.
Whelan, R. (2008). Effective analysis of reaction time data. The Psychological Record, 58(3), 475-482.
Wille, S. M. R., Di Fazio, V., Toennes, S. W., van Wel, J. H. P., Ramaekers, J. G., & Samyn, N. (2015). Evaluation of Δ9-tetrahydrocannabinol detection using DrugWipe5S® screening and oral fluid quantification after Quantisal™ collection for roadside drug detection via a controlled study with chronic cannabis users. Drug Testing and Analysis, 7(3), 178-186.
World Health Organisation. (2010). International Statistical Classification of Diseases 10th Revision. Geneva: Author. Retrieved from. www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf
World Health Organisation. (2017). Annex 1: Report on WHO Questionnaire for Review of Psychoactive Substances for the 39th ECDD: Evaluation of Cannabidiol. Geneva: Author. Retrieved from. www.who.int/medicines/access/controlled-substances/5.2_Cannabidiol_Annex1.pdf
Wray, L., Stott, C., Jones, N., & Wright, S. (2017). Cannabidiol does not convert to Δ(9)-tetrahydrocannabinol in an in vivo animal model. Cannabis and Cannabinoid Research, 2(1), 282-287.
Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., & Watanabe, K. (2011). Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety. Life Sciences, 88(15-16), 730-736.
Yi, P., Hsiao, Y., Tsai, C., Jan, T., Lu, C., & Chang, F. (2008). Serotonergic system in the central nucleus of amygdala mediates cannabidiol-induced sleep alteration. The Open Sleep Journal, 1, 58-68.
Zuardi, A., Cosme, R., Graeff, F., & Guimaraes, F. (1993). Effects of ipsapirone and cannabidiol on human experimental anxiety. Journal of Psychopharmacology, 7(1S), 82-88.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., … Tumas, V. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of Psychopharmacology, 23(8), 979-983.